Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 3/2007

01.03.2007 | Clinical Investigation

Clear graft survival and immune reactions following emergency keratoplasty

verfasst von: P. Maier, D. Böhringer, T. Reinhard

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Emergency penetrating keratoplasty is said to have a poorer outcome than conventional keratoplasty. We performed a retrospective analysis of 272 cases of emergency keratoplasty to evaluate this hypothesis.

Methods

We analysed 272 cases of emergency keratoplasty and compared the results with a control group of 1,257 scheduled normal-risk keratoplasties and 407 scheduled high-risk keratoplasties. Kaplan-Meier estimations were performed to estimate the percentage of clear graft survival and development of immune reactions. Indications for emergency keratoplasty were microbial diseases (n=109, acanthamoeba, bacteria, fungi), herpes simplex virus infections (n=83), ulcers due to immunological diseases (n=63), and 17 cases of ulcers of unknown origin.

Results

Within 1,500 postoperative days, grafts following emergency keratoplasty suffered statistically significantly more graft failures (clear graft survival, 67.9 vs. 86.9%, P<0.01) and immune reactions (grafts free from immune reactions, 62.8 vs. 78.6%, P<0.01) than grafts following scheduled, normal-risk keratoplasty. There was no statistically significant difference between emergency and scheduled high-risk keratoplasties (clear graft survival, 67.9 vs. 70.2%, and grafts free from immune reactions, 62.8 vs. 66.8%). For emergency keratoplasties, systemic immunosuppression (with cyclosporin A and/or mycophenolatmophetil) had a statistically significant positive effect on clear graft survival (77.4 vs. 63.5%, P=0.01), but not on the development of immune reactions (62.8 vs. 62.3%). A sub-group analysis showed that the effect on clear graft survival was mainly an effect on the underlying systemic immunological disease that had lead to emergency keratoplasty.

Conclusion

This retrospective analysis revealed that clear graft survival is limited following emergency keratoplasty. As in high-risk situations, systemic immunosuppression may be the key to improving prognosis following emergency keratoplasty in the long run.
Literatur
1.
Zurück zum Zitat Behrens-Baumann W (1984) [Results of keratoplasty a chaud]. Klin Monatsbl Augenheilkd 185:25–27PubMed Behrens-Baumann W (1984) [Results of keratoplasty a chaud]. Klin Monatsbl Augenheilkd 185:25–27PubMed
2.
Zurück zum Zitat Bialasiewicz AA, Naumann GO (1989) [Systemic cyclosporin A therapy in high risk keratoplasty]. Fortschr Ophthalmol 86:574–580PubMed Bialasiewicz AA, Naumann GO (1989) [Systemic cyclosporin A therapy in high risk keratoplasty]. Fortschr Ophthalmol 86:574–580PubMed
3.
Zurück zum Zitat Cobo LM, Coster DJ, Rice NS, Jones BR (1980) Prognosis and management of corneal transplantation for herpetic keratitis. Arch Ophthalmol 98:1755–1759PubMed Cobo LM, Coster DJ, Rice NS, Jones BR (1980) Prognosis and management of corneal transplantation for herpetic keratitis. Arch Ophthalmol 98:1755–1759PubMed
4.
Zurück zum Zitat Ficker LA, Kirkness CM, Rice NS, Steele AD (1989) The changing management and improved prognosis for corneal grafting in herpes simplex keratitis. Ophthalmology 96:1587–1596PubMed Ficker LA, Kirkness CM, Rice NS, Steele AD (1989) The changing management and improved prognosis for corneal grafting in herpes simplex keratitis. Ophthalmology 96:1587–1596PubMed
5.
Zurück zum Zitat Ficker LA, Kirkness C, Wright P (1993) Prognosis for keratoplasty in acanthamoeba keratitis. Ophthalmology 100:105–110PubMed Ficker LA, Kirkness C, Wright P (1993) Prognosis for keratoplasty in acanthamoeba keratitis. Ophthalmology 100:105–110PubMed
6.
Zurück zum Zitat Fine M, Cignetti FE (1977) Penetrating keratoplasty in herpes simplex keratitis. Recurrence in grafts. Arch Ophthalmol 95:613–616PubMed Fine M, Cignetti FE (1977) Penetrating keratoplasty in herpes simplex keratitis. Recurrence in grafts. Arch Ophthalmol 95:613–616PubMed
7.
Zurück zum Zitat Foster CS, Duncan J (1981) Penetrating keratoplasty for herpes simplex keratitis. Am J Ophthalmol 92:336–343PubMed Foster CS, Duncan J (1981) Penetrating keratoplasty for herpes simplex keratitis. Am J Ophthalmol 92:336–343PubMed
8.
Zurück zum Zitat Hill JC (1994) Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology 101:128–133PubMed Hill JC (1994) Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology 101:128–133PubMed
9.
Zurück zum Zitat Hoffmann F (1976) [Suture technique for perforating keratoplasty (author’s transl)]. Klin Monatsbl Augenheilkd 169:584–590PubMed Hoffmann F (1976) [Suture technique for perforating keratoplasty (author’s transl)]. Klin Monatsbl Augenheilkd 169:584–590PubMed
10.
Zurück zum Zitat Killingsworth DW, Stern GA, Driebe WT, Knapp A, Dragon DM (1993) Results of therapeutic penetrating keratoplasty. Ophthalmology 100:534–541PubMed Killingsworth DW, Stern GA, Driebe WT, Knapp A, Dragon DM (1993) Results of therapeutic penetrating keratoplasty. Ophthalmology 100:534–541PubMed
11.
Zurück zum Zitat Kirkness CM, Ficker LA, Steele AD, Rice NS (1991) The role of penetrating keratoplasty in the management of microbial keratitis. Eye 5 (Pt 4):425–431PubMed Kirkness CM, Ficker LA, Steele AD, Rice NS (1991) The role of penetrating keratoplasty in the management of microbial keratitis. Eye 5 (Pt 4):425–431PubMed
12.
Zurück zum Zitat Mayer K, Reinhard T, Reis A, Voiculescu A, Sundmacher R (2003) Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol 241:1051–1054PubMedCrossRef Mayer K, Reinhard T, Reis A, Voiculescu A, Sundmacher R (2003) Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol 241:1051–1054PubMedCrossRef
13.
Zurück zum Zitat Nobe JR, Moura BT, Robin JB, Smith RE (1990) Results of penetrating keratoplasty for the treatment of corneal perforations. Arch Ophthalmol 108:939–941PubMed Nobe JR, Moura BT, Robin JB, Smith RE (1990) Results of penetrating keratoplasty for the treatment of corneal perforations. Arch Ophthalmol 108:939–941PubMed
14.
Zurück zum Zitat Polack FM, Kaufman HE (1972) Penetrating keratoplasty in herpetic keratitis. Am J Ophthalmol 73:908–913PubMed Polack FM, Kaufman HE (1972) Penetrating keratoplasty in herpetic keratitis. Am J Ophthalmol 73:908–913PubMed
15.
Zurück zum Zitat Price FW Jr, Whitson WE, Johns S, Gonzales JS (1996) Risk factors for corneal graft failure. J Refract Surg 12:134–143; discussion 143–147PubMed Price FW Jr, Whitson WE, Johns S, Gonzales JS (1996) Risk factors for corneal graft failure. J Refract Surg 12:134–143; discussion 143–147PubMed
16.
Zurück zum Zitat Reinhard T, Reis A, Bohringer D, Malinowski M, Voiculescu A, Heering P, Godehardt E, Sunmacher R (2001) Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years’ results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 239:367–372PubMed Reinhard T, Reis A, Bohringer D, Malinowski M, Voiculescu A, Heering P, Godehardt E, Sunmacher R (2001) Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years’ results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 239:367–372PubMed
17.
Zurück zum Zitat Reinhard T, Sundmacher R (1992) [Perforating keratoplasty in endogenous eczema. An indication for systemic cyclosporin A—a retrospective study of 18 patients]. Klin Monatsbl Augenheilkd 201:159–163PubMed Reinhard T, Sundmacher R (1992) [Perforating keratoplasty in endogenous eczema. An indication for systemic cyclosporin A—a retrospective study of 18 patients]. Klin Monatsbl Augenheilkd 201:159–163PubMed
18.
Zurück zum Zitat Reinhard T, Sundmacher R, Godehardt E, Heering P (1997) [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor]. Ophthalmologe 94:496–500PubMedCrossRef Reinhard T, Sundmacher R, Godehardt E, Heering P (1997) [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor]. Ophthalmologe 94:496–500PubMedCrossRef
19.
Zurück zum Zitat Reinhard T, Sundmacher R, Heering P (1996) Systemic ciclosporin A in high-risk keratoplasties. Graefes Arch Clin Exp Ophthalmol 234 Suppl 1:S115–S121PubMedCrossRef Reinhard T, Sundmacher R, Heering P (1996) Systemic ciclosporin A in high-risk keratoplasties. Graefes Arch Clin Exp Ophthalmol 234 Suppl 1:S115–S121PubMedCrossRef
20.
Zurück zum Zitat Reis A, Reinhard T, Voiculescu A, Kutkuhn B, Godehardt E, Spelsberg H, Althaus C, Sundmacher R (1999) Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol 83:1268–1271PubMedCrossRef Reis A, Reinhard T, Voiculescu A, Kutkuhn B, Godehardt E, Spelsberg H, Althaus C, Sundmacher R (1999) Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol 83:1268–1271PubMedCrossRef
21.
Zurück zum Zitat Stubiger N, Pleyer U, Erb C, Thiel HJ (1995) [Keratoplasty a chaud]. Ophthalmologe 92:427–432PubMed Stubiger N, Pleyer U, Erb C, Thiel HJ (1995) [Keratoplasty a chaud]. Ophthalmologe 92:427–432PubMed
22.
Zurück zum Zitat Volker-Dieben HJ, Kok-van Alphen CC, D’Amaro J, de Lange P (1984) The effect of prospective HLA-A and -B matching in 288 penetrating keratoplasties for herpes simplex keratitis. Acta Ophthalmol (Copenh) 62:513–523CrossRef Volker-Dieben HJ, Kok-van Alphen CC, D’Amaro J, de Lange P (1984) The effect of prospective HLA-A and -B matching in 288 penetrating keratoplasties for herpes simplex keratitis. Acta Ophthalmol (Copenh) 62:513–523CrossRef
Metadaten
Titel
Clear graft survival and immune reactions following emergency keratoplasty
verfasst von
P. Maier
D. Böhringer
T. Reinhard
Publikationsdatum
01.03.2007
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 3/2007
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-006-0410-7

Weitere Artikel der Ausgabe 3/2007

Graefe's Archive for Clinical and Experimental Ophthalmology 3/2007 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.